

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 May 2022 (12.05.2022)



(10) International Publication Number
WO 2022/099257 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 39/00 (2006.01)

C07K 16/28 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/072193

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

02 November 2021 (02.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/109,305 03 November 2020 (03.11.2020) US

63/239,108 31 August 2021 (31.08.2021) US

(71) Applicant: **SANOFI-AVENTIS U.S. LLC** [US/US]; 55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors; and

(71) Applicants: **SEMIOND, Dorothee** [—/US]; c/o SANOFI, 54, rue La Boétie, 75008 Paris (FR). **THAI, Hoai-Thu** [FR/FR]; c/o SANOFI, 54, rue La Boétie, 75008 Paris (FR). **VAN DE VELDE, Helgi** [—/BE]; c/o SANOFI, 54, rue La Boétie, 75008 Paris (FR). **VEYRAT-FOLLET, Christine** [FR/FR]; c/o SANOFI, 54, rue La Boétie, 75008 Paris (FR).

(74) Agent: **ONUFRIYK, Christina** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: USE OF ISATUXIMAB FOR THE TREATMENT OF MULTIPLE MYELOMA

(57) Abstract: The present disclosure provides methods for treating multiple myeloma that comprise administering isatuximab to the individual at a dose of 10 mg/kg on Days 1, 8, 15, and 22 of a first 28-day cycle; administering the isatuximab at a dose of 10 mg/kg on Days 1 and 15 of a 28-day cycle, e.g., for at least 11 cycles, or e.g., until the individual achieves or is determined to achieve at least Very Good Partial Response (VGPR) to treatment; and administering the isatuximab at a dose of 10 mg/kg once every 28 days of one or more additional 28-day cycles.

WO 2022/099257 A1